

COMMENT OPEN



If there is not one cure for schizophrenia, there may be many

Carina Seah^{1,2,3} and Kristen J. Brennand^{1,2,3,4,5,6}✉

npj Schizophrenia (2020)6:11; https://doi.org/10.1038/s41537-020-0101-0

The diverse presentation of symptoms experienced by patients with schizophrenia is matched only by the complexity of the genetic architecture that underlies disease risk. To date, hundreds of rare^{1,2,3} and common^{4,5} genetic variants have been associated with schizophrenia. Growing evidence supports the link between genotype and patient outcome, portending a future of precision medicine in psychiatry.

Clinicians still engage in a slow trial-and-error process with each patient, in order to identify the most efficacious drug(s) with the fewest side effects; critically, 30% of cases show little response to first-line antipsychotics⁶. No genetic test can yet match patients to the most appropriate drug; however, patients with rare disruptive variants in gene targets of antipsychotics⁷ and/or higher schizophrenia polygenic risk scores (PRS)⁸ tend to show less improvement with antipsychotic drug treatment. Although all current antipsychotics are antagonists of dopamine receptor signaling, and genetic variation at the dopamine D₂ receptor may influence response to antipsychotic medications, the modest effect sizes at this locus have to date proven to be of limited clinical utility⁹. More promising, it is already possible to apply genetic markers to predict some adverse metabolic responses to antipsychotic treatment¹⁰.

We foresee a not-too-distant future whereby a combination of patient genotype, brain imaging and biomarkers efficiently pairs patients to their ideal drug. Already it is possible to apply structural or functional brain measures to stratify patients based on the severity of disease and/or drug response^{11–13}. Our expectation is that the predictive power of these circuit-based approaches will be further improved by considering patient genetics^{7,8} or imputed cell-type-specific gene expression^{14,15}. An emerging platform involves reprogramming of patient somatic cells to human induced pluripotent stem cells (hiPSCs), in order to empirically test pharmacological response of patient-derived brain cells in vitro¹⁶. Even without understanding the complex interactions between multifaceted risk variants underlying each patient's disease risk, researchers can systematically evaluate drug response in a donor and cell-type-specific manner. We hope that patient-specific phenotypic and/or transcriptomic drug screens will uncover novel drugs that act through mechanisms independent of dopamine biology. Most importantly, with an improved ability to predict which subset of patients will respond to which novel treatments, a successful drug need not be efficacious in all patients in order to be clinically useful.

Beyond drug response, hiPSC-based models allow for both targeted and large-scale functional validation of the growing list of variants thought to interact to contribute to schizophrenia risk. Rather than continuing to study disease risk variants one-at-a-time, CRISPR-based technologies can be applied to conduct forward genetic screens, simultaneously assessing the phenotypic impact of hundreds of genes in a single experiment. It is now possible to undertake large-scale studies of risk genes on neuronal

gene expression and function, in either pooled or arrayed formats¹⁷. Key candidate genes identified through such unbiased approaches can hint at points of convergence underlying schizophrenia risk that might represent novel therapeutic targets, or help to explain independent genetic mechanisms leading to disease. Resolving the causal variants underlying schizophrenia and treatment response should dramatically improve our ability to match patients to more effective treatments.

The complex heterogeneity of schizophrenia means that a single cure may not be found. New strategies to stratify etiologically complex patients, diagnosing high-risk individuals prior to psychosis onset, makes possible a future whereby we prevent, rather than treat, schizophrenia. Ultimately, tailoring interventions for each patient achieves the potential of precision medicine, treating schizophrenia with not one silver-bullet drug, but many.

Received: 11 November 2019; Accepted: 28 February 2020;

Published online: 20 April 2020

REFERENCES

1. Marshall, C. R. et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat. Genet.* **49**, 27–35 (2017).
2. Rees, E. et al. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. *Nat. Neurosci.* **23**, 179–184 (2020).
3. Singh, T. et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat. Neurosci.* **19**, 571–577 (2016).
4. Ripke, S., Group, S. W. & O'Donovan, M. Current status of schizophrenia GWAS. *Eur. Neuropsychopharmacol.* **27**, S415 (2017).
5. Pardini, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat. Genet.* <https://doi.org/10.1038/s41588-018-0059-2> (2018).
6. Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A. & MacCabe, J. H. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. *BMC Psychiatry* **17**, 12 (2017).
7. Ruderfer, D. M. et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. *Lancet Psychiatry* **3**, 350–357 (2016).
8. Zhang, J. P. et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. *Am. J. Psychiatry* **176**, 21–28 (2019).
9. Zhang, J. P. et al. Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis. *Schizophr. Bull.* **41**, 1248–1255 (2015).
10. Mittal, K. et al. A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. *Schizophr. Res.* **187**, 67–73 (2017).
11. Sarpal, D. K. et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. *Am. J. Psychiatry* **173**, 69–77 (2016).
12. Reis Marques, T. et al. White matter integrity as a predictor of response to treatment in first episode psychosis. *Brain* **137**, 172–182 (2014).
13. Hadley, J. A. et al. Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. *Neuropsychopharmacol.ogy* **39**, 1020–1030 (2014).

¹Graduate School of Biomedical Science, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ²Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ³Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ⁴Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ⁵Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ⁶Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ✉email: kristen.brennand@mssm.edu

14. Huckins, L. M. et al. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. *Nat. Genet.* **51**, 659–674. <https://doi.org/10.1038/s41588-019-0364-4> (2019).
15. Gusev, A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. *Nat. Genet.* **50**, 538–548 (2018).
16. Readhead, B. et al. Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. *Nat. Commun.* **9**, 4412 (2018).
17. Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. *Neuron* <https://doi.org/10.1016/j.neuron.2019.07.014> (2019).

ACKNOWLEDGEMENTS

This work was partially supported by National Institute of Health (NIH) grants R56 MH101454 (K.J.B.), R01 MH106056 (K.J.B.), and R01 MH109897 (K.J.B.).

AUTHOR CONTRIBUTIONS

C.S. and K.J.B. wrote the paper.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to K.J.B.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020